Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer A G Ord (OP:BAYZF)

52.50 -1.35 (-2.51%)
Streaming Delayed Price Updated: 9:30 AM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 231
Open 52.50
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 53.85
Today's Range 52.50 - 52.50
52wk Range 29.16 - 58.33
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bayer and Iambic Collaborate to Advance Drug Discovery with AI
From Bayer
Via Business Wire
News headline image
Bayer Completes Acquisition of Perfuse Therapeutics
From Bayer
Via Business Wire

Performance

YTD
+16.9%
+16.9%
1 Month
+22.1%
+22.1%
3 Month
+20.3%
+20.3%
6 Month
+26.2%
+26.2%
1 Year
+71.3%
+71.3%

More News

Read More
News headline image
Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief
From Bayer
Via Business Wire
News headline image
Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions
From Bayer
Via Business Wire
News headline image
Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business
From Bayer
Via Business Wire
News headline image
Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth
From Bayer
Via Business Wire
News headline image
Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease
From Bayer
Via Business Wire
News headline image
Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
From Bayer
Via Business Wire
News headline image
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
From Bayer
Via Business Wire
News headline image
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
From Bayer
Via Business Wire
News headline image
Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
From Bayer
Via Business Wire
News headline image
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
From Bayer
Via Business Wire
News headline image
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
From Bayer
Via Business Wire
News headline image
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
From Bayer
Via Business Wire
News headline image
Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
From Bayer
Via Business Wire
News headline image
Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities
From Bayer
Via Business Wire
News headline image
Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
From Bayer
Via Business Wire
News headline image
Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
From Bayer
Via Business Wire
News headline image
Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian
From Bayer
Via Business Wire
News headline image
New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing
From Bayer
Via Business Wire
News headline image
Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential
From Bayer
Via Business Wire
News headline image
Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris
From Bayer
Via Business Wire
News headline image
KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
From Bayer
Via Business Wire
News headline image
New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
From Bayer
Via Business Wire
News headline image
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
From Bayer
Via Business Wire

Frequently Asked Questions

Is Bayer A G Ord publicly traded?
Yes, Bayer A G Ord is publicly traded.
What exchange does Bayer A G Ord trade on?
Bayer A G Ord trades on the OTC Traded
What is the ticker symbol for Bayer A G Ord?
The ticker symbol for Bayer A G Ord is BAYZF on the OTC Traded
What is the current price of Bayer A G Ord?
The current price of Bayer A G Ord is 52.50
When was Bayer A G Ord last traded?
The last trade of Bayer A G Ord was at 06/26/26 09:30 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.